SCHEMBL20164138

SCHEMBL20164138

C=CCCC(=O)Nc1cc(C(=O)OC)ccc1NC(=O)C(CC=C)NC(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 4/20 0.41
▸ ALDH1A1 P00352 6/20 0.39
▸ KDM4E B2RXH2 5/20 0.39
▸ HPGD P15428 2/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ KMT2A Q03164 1/20 0.36
▸ MAPT P10636 3/20 0.36
▸ LMNA P02545 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA4 P22748 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ MDH1 P40925 2/20 0.35
▸ MDH2 P40926 2/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ ACE P12821 1/20 0.35
▸ PKM P14618 1/20 0.34
▸ TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20164137 1.00 AAK1 (0.41) AAK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL18330479 0.92 KDM4E (0.38) AAK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL20181256 0.86 AAK1 (0.43) AAK1MAPTSMN1; SMN2CA12CA1
SCHEMBL21442835 0.81 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDHSD17B10KMT2A
SCHEMBL1479187 0.72 SMN1; SMN2 (0.53) ALDH1A1KDM4EHPGDHSD17B10KMT2A
SCHEMBL16318447 0.71 KDM4E (0.52) ALDH1A1KDM4EHPGDHSD17B10KMT2A
SCHEMBL20164199 0.71 HDAC1 (0.52) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL20181226 0.71 AAK1 (0.55) AAK1MAPTSMN1; SMN2
SCHEMBL20164158 0.70 NPC1 (0.40) KDM4EKMT2AMAPT
SCHEMBL28619986 0.70 NPC1 (0.40) KDM4EKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3310777-B1 DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-10-09 — — EP disclosed
US-10160750-B2 Diamide macrocycles as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-12-25 — — US disclosed
US-20180141932-A1 DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-05-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141932-A1 DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F11 AAK1 1091/4885ALDH1A1 4091/4885KDM4E 603/4885
US-10160750-B2 Diamide macrocycles as factor XIa inhibitors TFPI, TFPI2, F11 AAK1 1091/4885ALDH1A1 4091/4885KDM4E 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback